Trials / Completed
CompletedNCT00515424
Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension
A Multicenter, Randomized, Placebo-Controlled, Latanoprost-Controlled, Parallel Group Study to Assess the Tolerability, Safety and Efficacy of RKI983 Ophthalmic Solution Given Twice a Day Over One Week in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RKI983 |
Timeline
- Start date
- 2007-07-01
- First posted
- 2007-08-13
- Last updated
- 2007-12-28
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00515424. Inclusion in this directory is not an endorsement.